Jeff Leiden transformed Vertex Pharmaceuticals from a struggling biotech with stock under $40 in 2012 into a leader with shares now above $500. As CEO and now executive chairman, he credited his success to a dual strategy of focusing only on validated drug targets and fostering a collaborative culture. He identified that most drug failures stemmed from targeting the wrong molecules, not missing them.
This led Vertex to prioritize proven targets, notably in cystic fibrosis. Leiden replaced the previous hub-and-spoke leadership model with a team-based approach, holding weekly six-hour meetings where direct reports debated issues openly. He encouraged cross-functional collaboration, breaking down silos between discovery, development, regulatory, and commercial teams.
He emphasized hiring the right people and cited Patrick Lencioni’s “The Five Dysfunctions of a Team” as essential reading. His philosophy was that drug discovery is a team sport, and everyone must “swim outside their own lanes.”.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing